Faculty Information |
|
Article types | Original article |
Language | English |
Refereed paper | Refereed |
Title | Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial |
Journal | Formal name:Jpn J Ophthalmol |
Volume, Number, Page | 67(3),pp.301-10 |
Papers・Author | Mori R, Honda S, Gomi F, Tsujikawa A, Koizumi H, Ochi H, Ohsawa S, Okada AA; TENAYA and LUCERNE Investigators |
Publication date | 2023/05 |
Papers・Description | 2023 May;67(3):301-310. doi: 10.1007/s10384-023-00985-w. Epub 2023 Apr 11. Erratum in: Jpn J Ophthalmol. 2023 May 8;: PMID: 37039948; PMCID: PMC10098238. |
DOI | 10.1007/s10384-023-00985-w |
PMID | 37039948 |